Characterization of bispecific T-cell Engager (BiTE) antibodies with a high-capacity T-cell dependent cellular cytotoxicity (TDCC) assay.

Autor: Nazarian AA; Therapeutic Discovery, Amgen Inc., Thousand Oaks, CA, USA aaronn@amgen.com., Archibeque IL; Oncology Research, Amgen Inc., Thousand Oaks, CA, USA., Nguyen YH; Therapeutic Discovery, Amgen Inc., Thousand Oaks, CA, USA., Wang P; Therapeutic Discovery, Amgen Inc., Thousand Oaks, CA, USA., Sinclair AM; Oncology Research, Amgen Inc., Thousand Oaks, CA, USA., Powers DA; Therapeutic Discovery, Amgen Inc., Thousand Oaks, CA, USA.

Publikováno v: Journal of biomolecular screening [J Biomol Screen] 2015 Apr; Vol. 20 (4), pp. 519-27. Date of Electronic Publication: 2014 Dec 04.